Century Therapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
Century Therapeutics, Inc. (IPSC) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-03-19
- Century Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-12-31 was $7.42M.
- Century Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-09-30 was $0.00.
- Century Therapeutics, Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-06-30 was $4.00M.
- Century Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Century Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $11.42M.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-19 | |||
| 2023-12-31 | $7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $7.42M derived: sum of 2 quarters · filed 2025-03-19 | $11.42M derived: sum of 3 quarters · filed 2025-03-19 | $11.42M 10-K · filed 2025-03-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.00M derived: sum of 2 quarters · filed 2024-11-05 | $4.00M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $4.00M 10-Q · filed 2024-11-05 | $4.00M 10-Q · filed 2024-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |